Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma

Table 3 Univariate and multivariate Cox regression analyses for PFS.

Characteristic	Univariate analysis			Multivariate analysis
Characteristic	HR	95%CI	P	HR	95%CI	P
Child–Pugh classification(B/A)	1.153	0.548 ∼ 2.426	0.708
No. of tumors (≥ 3/<3)	1.291	0.806 ∼ 2.067	0.288
Tumor diameter (≥ 5 cm/<5 cm)	1.092	0.673 ∼ 1.771	0.723
Portal vein tumor thrombus (yes/no)	1.928	0.991 ∼ 3.751	0.053	2.103	1.072 ∼ 4.125	0.031
Extrahepatic metastases(yes/no)	1.034	0.633 ∼ 1.689	0.893
AFP (≥ 400ng/mL/<400ng/mL)	1.299	0.831 ∼ 2.032	0.251
Treatment option (TACE + T/TACE + TC)	1.605	1.035 ∼ 2.488	0.034	1.621	1.045 ∼ 2.514	0.031
Interval of recurrence from initial treatment(<1 year/≥1 year)	0.519	0.305 ∼ 0.881	0.015	0.494	0.289 ∼ 0.844	0.010
MVI(Positive/Negative)	1.298	0.838 ∼ 2.008	0.242

AFP, a-fetoprotein; MVI, microvascular invasion; No. of tumors, number of tumors.

ISSN: 1471-2407